TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01432860

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In-person counseling
Description: The design is a 3 \[in-person training of patients and partners (PARTNER) vs. workbook training of patients and partners (WORKBOOK) vs. an assessment only group that receives education and treatment as usual care\] X 7 \[baseline, 4, 8, 12, 16, 20, and 24 month follow-up\] study. Standard education of melanoma patients, which are to be performed with the study partner, includes a recommendation to check moles and mark ones to remember on a body map. All participants receive the same measures and will be recruited using the same procedures, thus, yielding equivalence across conditions. Pairs will observe how to use their skin check tools and be asked to demonstrate their competence in using them.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Workbook
Description: Participants will read a workbook and perform skills training exercises.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tablet Computer-Based Education
Description: Participants will receive their education from an interactive app designed for a tablet computer.
Study: NCT03394807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Description: Levobupivacaine injection to Transversus abdominis plane and rectus sheath
Study: NCT04255498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: Perform Phase I study of etanercept (50 mg, once a week for 4 weeks), followed by mifepristone (300 mg, once a day for 7 days), followed by a 10 week observation period and assessment of safety, efficacy and biomarker response to therapy.~Perform dynamic modeling studies before and after 5 weeks of therapy, repeating the method used previously, in order to document the response to exercise and better quantify the degree of recovery in treated subjects using an exercise challenge and 9 point in time with blood and saliva collections over 24 hours with genomic, cytokine, neuropeptide and cell population studies.
Study: NCT03394807

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline injection to Transversus abdominis plane and rectus sheath
Study: NCT00372112

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GW642444
Description: GW642444H

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GW642444
Description: GW642444H

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GW642444
Description: GW642444H

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GW642444
Description: GW642444H

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered twice daily
Study: NCT02348606

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JZP-110

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JZP-110

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JZP-110

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JZP-110

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo oral tablet
Study: NCT02145364

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultherapy® treatment
Description: Microfocused ultrasound treatment
Study: NCT05038423

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 5R Shared Leadership Program
Description: The manualised 5RS program aims to develop the leadership qualities of peer leaders by teaching them how to create, embody, advance, and embed a collective sense of 'us' in their teams. More specifically, 5RS consists of two key components that involve (1) implementing a structure of shared leadership, and (2) strengthening the identity leadership skills of the appointed peer leaders (Fransen et al., 2020).~Fransen, K., Haslam, S. A., Steffens, N. K., Mallett, C. J., Peters, K., Mertens, N., \& Boen, F. (2020). All for us and us for all: Introducing the 5R Shared Leadership Program. Psychology of Sport and Exercise, 51, 101762. https://doi.org/10.1016/j.psychsport.2020.101762 Haslam, S. A., Steffens, N. K., Peters, K., Boyce, R. A., Mallett, C. J., \& Fransen, K. (2017). A social identity approach to leadership development: The 5R program. Journal of Personnel Psychology, 16(3), 113-124. https://doi.org/10.1027/1866-5888/a000176

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 12-week structured walking program
Description: Participants engaged in an evidence-based 12-week structured walking program, which aimed to enhance participants' physical activity and aerobic fitness levels based on personalised walking schedules and weekly group walks organised by the community-based meeting points.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 12-week structured walking program
Description: Participants engaged in an evidence-based 12-week structured walking program, which aimed to enhance participants' physical activity and aerobic fitness levels based on personalised walking schedules and weekly group walks organised by the community-based meeting points.
Study: NCT03296930

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sofosbuvir 400 MG Oral Tablet,
Description: Interferon free direct acting antiviral drugs used for treatment of HCV.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ombitasvir/paritaprevir/ritonavir
Description: Interferon free direct acting antiviral drugs used for treatment of HCV.
Study: NCT00543504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 2.5 mg/kg By Vein Over 90 Minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 2.5 mg/kg By Vein Over 90 Minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 2.5 mg/kg By Vein Over 90 Minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 2.5 mg/kg By Vein Over 90 Minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: 200 mg By Mouth Daily for 28 Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 50 mg By Mouth Daily for 28 Days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Loading 2 mg/kg by vein then Maintenance 1 mg/kg by vein on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: 250 mg By Mouth Daily for 21 Days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: 12.5 mg orally daily for 4 weeks, then 2 weeks off.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Loading 100 mg/m² by vein and Maintenance 75 mg/m² by vein on Days 1, 8, 15, 22
Study: NCT00629681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Pregabalin capsules; initial dose of 75 mg twice daily for 4 days. Dose could be increased based on individual patient's response and tolerability to 150 mg twice daily from Day 4 onwards, with a further increase to 300 mg twice daily from Day 14 onwards if needed. Total duration of treatment was 28 days.
Study: NCT02922556

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized Plasticity-Based Adaptive Cognitive Training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Commercially available computerized training
Study: NCT02202408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKI2670
Description: Oral, Single Dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Same shape as the experimental drug
Study: NCT03578159

Intervention type: OTHER
Intervention: Chhatralaya
Description: Chhatralaya, home for children provide living resources along with spiritual practices.
Study: NCT01050972

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral: Cognitive, Relaxation, Exercise Therapy
Description: Behavioral: Cognitive, Relaxation, Exercise Therapy The intervention consists of brief shoulder and neck exercises to be performed several times a day, a relaxation exercise and instructions of how to reduce hyperfunction of the craniofacial and cervical muscles during the day
Study: NCT01829191

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soft Contact Test Lens A
Description: FDA-approved, non-marketed daily disposable soft contact lens, conventional design

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soft Contact Test Lens C
Description: Daily disposable soft contact lens with new optical design
Study: NCT03546192

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone Quadrivalent Influenza Vaccine
Description: 0.5-mL, Intramuscular, SH 2015 formulation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone Quadrivalent Influenza Vaccine
Description: 0.5-mL, Intramuscular, SH 2015 formulation
Study: NCT04095845

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CO THA
Description: Replacement of arthritic hip with artificial implant using CT-based navigation and conventional technique

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mako THA
Description: Replacement of arthritic hip with artificial implant using mako robotic-arm assist
Study: NCT02266225

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lifestyle-integrated Functional Exercise
Description: Lifestyle-integrated functional exercise- one individual and four group-based sessions led by a physiotherapist over two months, and two phone calls one week and one month following final group-based exercise session.
Study: NCT02205814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fasitibant- low dose
Description: Single intra-articular injection of low dose of fasitibant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fasitibant- intermediate dose
Description: Single intra-articular injection of intermediate dose of fasitibant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fasitibant- high dose
Description: Single intra-articular injection of high dose of fasitibant

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Single intra-articular injection of placebo
Study: NCT03766308

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Highland Barley Diet
Description: Highland Barley Diet

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ADA diet
Description: ADA diet
Study: NCT02455622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elaprase for intravenous (IV) infusion
Description: Patients enrolled in this study will receive once-weekly IV infusions of Elaprase at a dose of 0.5 mg/kg and will be followed for a minimum of 5 years after initiation of Elaprase treatment, or until they reach their 10th birthday, whichever is longer.Height and weight data from HOS will be utilized in the Primary Growth Analysis for this study.
Study: NCT04069091

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 'Enjoy your Bump' (iloodottaa.fi) online self-help intervention
Description: The intervention employs elements of cognitive behavioral therapy: empathic, clear and sensitive communication with women and their families, problem self-formulation of solutions to problems, behavioral activation, identification and changing negative automated negative thoughts, addressing low confidence, and promoting problem- solving and relapse prevention.~The Enjoy your Bump intervention has been adapted to the Finnish culture and healthcare setting (ilodottaa.fi).
Study: NCT04084301

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High CPB flow
Description: Target CPB flow 2.9 L/min/m2 throughout the CPB period
Study: NCT00642460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 8mg/kg (patients\>=30kg) or 12mg/kg (patients \<30kg) iv every 2 weeks. In Part III, administration frequency may be reduced to every 3 and every 4 weeks, respectively, according to an optional alternative dosing schedule.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: iv every 2 weeks for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-steroidal anti-inflammatory drugs (NSAIDs)
Description: as prescribed

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Non-steroidal anti-inflammatory drugs (NSAIDs)
Description: as prescribed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: as prescribed

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: methotrexate
Description: as prescribed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corticosteroids
Description: orally, as prescribed

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: corticosteroids
Description: orally, as prescribed
Study: NCT02518958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RRx-001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study: NCT02633254

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance guided High Intensity Focused Ultrasound
Description: Targeted vessel ablation of type 3 uterine fibroids with magnetic resonance guided high intensity focused ultrasound
Study: NCT02124018

Intervention type: PROCEDURE
Intervention: Programmed ventricular stimulation
Description: Programmed ventricular stimulation in high-risk patients based on non-invasive evaluation

Intervention type: DEVICE
Intervention: ICD implantation
Description: ICD implantation in patients with induced VT in programmed ventricular stimulation
Study: NCT03878030

Intervention type: DRUG
Intervention: nusinersen
Description: Subjects will receive nusinersen and be observed with motor assessments for 24 months
Study: NCT02183337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1356

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BI 1356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1356 + Pioglitazone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BI 1356 + Pioglitazone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Study: NCT02507180

Intervention type: OTHER
Intervention: LEFt clinical decision rule
Description: The LEFt rule~Predictor Points Left leg symptoms +1 Extremity swelling (≥ 2 cm difference in calf circumference +1 First trimester symptom onset +1~Clinical probability Unlikely: 0 or 1 point Likely: \> 1 point
Study: NCT01165788

Intervention type: PROCEDURE
Intervention: Semi structured personal interview
Description: A trained research assistant will conduct in-person, in-depth semi-structured interviews at a location of the participants choosing. Participants will be asked to discuss their experiences with cancer, focusing especially on how their cancer affected their (1) work/education (2) relationships with their family (spouse, children, parents, siblings and other relatives) (3) their other social relationships
Study: NCT02027818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green
Description: Observation of the correlation between fluorescence and margins of the tumour after IV injection of ICG
Study: NCT00993512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amphinex (TPCS2a)
Description: intravenous TPCS2a, followed by standard dose of bleomycin (iv infusion) and illumination with CeramOptec laser.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin
Description: intravenous TPCS2a, followed by standard dose of bleomycin (iv infusion) and illumination with CeramOptec laser.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Illumination with CeramOptec laser
Description: intravenous TPCS2a, followed by standard dose of bleomycin (iv infusion) and illumination with CeramOptec laser.
Study: NCT00835640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexofenadine 180 mg tablets
Description: 1 x 180 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALLEGRA® 180 mg tablets
Description: 1 x 180 mg
Study: NCT03465462

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: group/arm C (control group)
Description: Group C in the third stage (30 days) continued drug use with no change in diet and no mineral supplementation.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: group/arm D (diet group)
Description: Group D in the third stage (30 days) received an optimal-mineral-content properly balanced diet enriched in food with high zinc content.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: group/arm S (supplementation group)
Description: Group S in the third stage (30 days) received zinc supplementation as one capsule containing 15 mg of Zn taken orally once a day in the morning, two hours after antihypertensive drug administration with no change in diet.
Study: NCT02638389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: evaluate the efficacy and safety of sirolimus in these patients
Study: NCT02495246

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ChAd3-EBO-Z

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ChAd3-EBO-Z

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ChAd3-EBO-Z

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ChAd3-EBO-Z

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ad26.ZEBOV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ad26.ZEBOV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ad26.ZEBOV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ad26.ZEBOV
Study: NCT00420615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patupilone and Omeprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patupilone + Midalzolam
Study: NCT03401567

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise group
Description: Elbow bending exercises with blood flow restriction will be performed to the exercise group during 6 weeks for 3 times a week. The first set of exercises will be 30 repetitions then 3 sets of 15 repetitions. Totally 75 repetitions will be performed. 30 seconds rest interval between sets will be given.
Study: NCT03409211

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: PEVCO
Description: All subjects will receive PEVCO for 6 more weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: PEVCO
Description: All subjects will receive PEVCO for 6 more weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Supplement Capsules without Coconut Oil
Description: All subjects will receive placebo (PBO) for 3 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Supplement Capsules without Coconut Oil
Description: All subjects will receive placebo (PBO) for 3 weeks
Study: NCT02321189

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LONGEVINEX
Description: let everyone of the participants oral 1 capsule containing 100 mg LONGEVINEX

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: let everyone of the participants oral 1 capsule containing 100 mg placebo
Study: NCT03262025

Intervention type: PROCEDURE
Intervention: Operated
Description: Patients were either managed conservatively or underwent emergency laparotomy

Intervention type: PROCEDURE
Intervention: Operated
Description: Patients were either managed conservatively or underwent emergency laparotomy
Study: NCT03172806

Intervention type: DIAGNOSTIC_TEST
Intervention: Polysomnography
Description: To compare the ability of the clinical scores, all patients included in this study underwent a polysomnography.
Study: NCT03394599

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TheraTrainer + Motiview
Description: TheraTrainer will be used in conjunction with Motiview.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TheraTrainer Only
Description: TheraTrainer will be used.
Study: NCT00931723

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine fumarate XR
Description: Oral treatment, once daily, Day 1 = 300 mg, Day 2 and thereafter 600 mg. Dose might be adjusted as from Day 3 by the discretion of the investigator.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Quetiapine fumarate XR
Description: Oral treatment, once daily, Day 1 = 300 mg, Day 2 and thereafter 600 mg. Dose might be adjusted as from Day 3 by the discretion of the investigator.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lithium
Description: Oral treatment, twice daily, Days 1 and 2 = 600 mg/day, Days 3-8 = 900 mg/day. Dose adjustment from day 9 to end of study will be at the discretion of the investigator.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral treatment twice daily.
Study: NCT02629848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Motesanib
Description: Motesanib (AMG 706) 5 x 25 mg tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Motesanib placebo-matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin IV
Study: NCT03937648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COL-144 50mg
Description: COL-144 50mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COL-144 100mg
Description: COL-144 100mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COL-144 200mg
Description: COL-144 200mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COL-144 400mg
Description: COL-144 400mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01774253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Study: NCT03381365

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CuraSeal Percutaneous Intraluminal Closure System
Study: NCT01402076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tasimelteon
Description: 20mg daily dosing, Days 4-20

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tasimelteon
Description: 20mg daily dosing, Days 4-20

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Description: 4mg, single dose, Days 3 and 20

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Description: 4mg, single dose, Days 3 and 20

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: 10mg, single dose, Days 1 and 18

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: 10mg, single dose, Days 1 and 18